ArticleJAMA network open2020
Assessment of Trends in Cigarette Smoking Cessation After Cancer Diagnosis Among US Adults, 2000 to 2017.
Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Reach, Acceptability, and Effectiveness of Proactive Outreach and Varenicline with Cancer-Focused Counseling for Patients with Cancer: A Pilot Randomized Comparative Effectiveness Trial.JCO oncology advances · 2026Article
- Patterns of exclusive, dual and poly tobacco products use among cancer survivors in the United States.Journal of cancer survivorship : research and practice · 2025Article
- Association of life-course socioeconomic status with lifestyle changes after diagnosis of non-communicable disease: a prospective study using data from European, United States, and Chinese cohorts.American journal of epidemiology · 2025Article
- Smoking Cessation and Mortality Risk in Cancer Survivorship: Real-World Data From a National Cancer Institute-Designated Cancer Center.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Observational
- Tobacco Assessment in Actively Accruing National Cancer Institute Clinical Trials Network Trials.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Article
- Specialty Tobacco Treatment Implementation in Oncology: A Qualitative Study.JCO oncology practice · 2025Article
- Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials.Journal of pain and symptom management · 2025Article
- Longitudinal Results From the Nationwide Just ASK Initiative to Promote Routine Smoking Assessment in American College of Surgeons-Accredited Cancer Programs.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants.Cancer · 2025Article
- Spanish Society of Medical Oncology recommendations for comprehensive assessment and care of cancer survivors' needs.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Smoking patterns and the intention to quit in German cancer patients: a cross-sectional study.BMC cancer · 2024Article
- Current Practices, Perceived Barriers, and Promising Implementation Strategies for Improving Quality of Smoking Cessation Support in Accredited Cancer Programs of the American College of Surgeons.JCO oncology practice · 2024Article
- Article
- Tobacco use and cancer-related symptom burden: Analysis of the US Population Assessment of Tobacco and Health Study.Cancer · 2023Article
- The impact of having a relative or a friend with cancer on person's modifiable cancer-related risk factors.Irish journal of medical science · 2023Article
- Integrating Tobacco Treatment Into Oncology Care: Reach and Effectiveness of Evidence-Based Tobacco Treatment Across National Cancer Institute-Designated Cancer Centers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Smoking patterns and the intention to quit in German patients with cancer: study protocol for a cross-sectional observational study.BMJ open · 2023Article
- Cigarette smoking in childhood and risk of all-cause and cause-specific mortality in adulthood.Frontiers in public health · 2023Article
- Supporting Smokers in Difficult Settings: Suggestions for Better Education and Counseling in Cancer Centers in Jordan.Current oncology (Toronto, Ont.) · 2022Article
- Health behavior changes and mortality among South Korean cancer survivors.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Importance: Continued cigarette smoking after cancer diagnosis has been shown to adversely alter the cancer survivor's health outcomes and quality of life. Although considerable progress has been made in reducing cigarette smoking in the United States over the last decades, trends in cigarette smoking cessation among cancer survivors have not yet been fully investigated. Objective: To evaluate temporal trends in cigarette smoking cessation and their sociodemographic and behavioral correlates in the US population of adult cancer survivors. Design, Setting, and Participants: This investigation was a serial cross-sectional study of the National Health Interview Survey (NHIS) from 2006 to 2018, a household survey of civilian US residents who were 18 years or older. Data analysis was performed from June to October 2019. The NHIS is population based and representative of the US population. Included in this study were 381 989 respondents to the NHIS in 2006 to 2018. Main Outcomes and Measures: The primary outcome was the probability of quitting cigarette smoking after first cancer diagnosis. Secondary outcomes were factors associated with quitting cigarette smoking after cancer diagnosis. Results: Data on 381 989 adults (weighted N = 239 114 051; mean [SD] age, 48.96 [18.28] years; 211 508 [55.37%] female; 61.90% non-Hispanic White, 13.97% non-Hispanic Black, and 16.22% Hispanic individuals) 18 years or older were analyzed from the 2006 to 2018 NHIS, of whom 8.80% (n = 35 524; weighted n = 21 016 720) were diagnosed with cancer. Among cancer survivors diagnosed between 2000 and 2017, the age-adjusted prevalence of current cigarette smoking at the time of first cancer diagnosis was 24.45% (n = 4054; weighted n = 2 395 173). The probability of reporting a cigarette smoking cessation event after first cancer diagnosis statistically significantly increased with each year of cancer diagnosis (hazard ratio [HR], 1.05; 95% CI, 1.02-1.08), indicating upward trends in the prevalence of quitting cigarette smoking over time. Older individuals (HR, 1.02; 95% CI, 1.01-1.03), individuals diagnosed as having a smoking-related cancer (HR, 1.28; 95% CI, 1.06-1.54), individuals with an undergraduate degree (HR, 1.39; 95% CI, 1.08-1.79) or a postgraduate degree (HR, 1.61; 95% CI, 1.18-2.20), and individuals with obesity (HR, 1.32; 95% CI, 1.06-1.63) had a higher probability of reporting a cigarette smoking cessation event after cancer diagnosis, whereas individuals living below the poverty level (HR, 0.62; 95% CI, 0.48-0.81) had a lower probability of reporting a cigarette smoking cessation event after cancer diagnosis. Conclusions and Relevance: In this nationally representative survey of the US adult population, the likelihood of cigarette smoking cessation among cancer survivors increased with the year of cancer diagnosis from 2000 to 2017; however, the improvement is incremental, and the prevalence of smoking remained high among this population. Considering the projected increase in the population of cancer survivors in the United States, urgent action is needed to increase cigarette smoking cessation rates in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.